Uc-crc Mouse Model

Azoxymethane serves as the carcinogenic initiating agent, while dextran sulfate sodium produces injury to the colonic epithelium and promotes relapsing inflammation. Their combination models a sequence in which initiated cells encounter repeated inflammatory damage and repair. This separation of initiation from inflammation helps investigators examine how colitis can influence the progression from epithelial injury toward dysplasia and tumor formation.

Repeated DSS-associated injury creates cycles of damage, inflammation, and epithelial repair rather than a single transient insult. Continued repair occurs in an inflammatory environment, allowing researchers to study how persistent tissue stress and inflammatory signaling contribute to abnormal tissue changes. These cycles are therefore central to modeling the relationship between chronic colitis and later colorectal tumor development.

The model permits analysis of immune responses alongside direct injury to the colonic epithelium. Inflammation can alter the repair environment, while repeated epithelial damage provides an ongoing stimulus for inflammatory signaling. Studying both processes together helps clarify how immune activity, tissue disruption, and epithelial responses interact during the transition from chronic intestinal inflammation to dysplasia and cancer.

A typical workflow uses azoxymethane to initiate colorectal carcinogenesis, followed by cycles of dextran sulfate sodium exposure that injure the colon and induce relapsing inflammation. The resulting animals are examined for inflammatory changes, dysplasia, and tumors. This staged design allows investigators to connect carcinogenic initiation with subsequent inflammation-driven progression rather than evaluating either process in isolation.

Researchers would select the Uc-CRC mouse model when a study concerns colorectal cancer arising in the setting of chronic colitis. It supports testing of preventive strategies, anti-inflammatory treatments, and anticancer therapies within the same experimental framework. The model is especially useful when the research question focuses on whether modifying inflammation or related molecular pathways changes tumor development.

Studies can use this system to examine changes in intestinal inflammation, immune responses, epithelial injury and repair, dysplasia, and tumor formation. These outcomes help determine whether an intervention affects early inflammatory processes, later cancer progression, or both. Molecular pathway analysis can further connect observed tissue and tumor changes with mechanisms relevant to inflammation-driven colorectal cancer.